| Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of … WA Peters III, PY Liu, RJ Barrett, RJ Stock, BJ Monk, JS Berek, L Souhami, ... Obstetrical & Gynecological Survey 55 (8), 491-492, 2000 | 2806 | 2000 |
| Incorporation of bevacizumab in the primary treatment of ovarian cancer RA Burger, MF Brady, MA Bookman, GF Fleming, BJ Monk, H Huang, ... New England Journal of Medicine 365 (26), 2473-2483, 2011 | 2752 | 2011 |
| Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ... New England Journal of Medicine 375 (22), 2154-2164, 2016 | 2397 | 2016 |
| Niraparib in patients with newly diagnosed advanced ovarian cancer A González-Martín, B Pothuri, I Vergote, R DePont Christensen, ... New England Journal of Medicine 381 (25), 2391-2402, 2019 | 1690 | 2019 |
| Improved survival with bevacizumab in advanced cervical cancer KS Tewari, MW Sill, HJ Long III, RT Penson, H Huang, LM Ramondetta, ... New England Journal of Medicine 370 (8), 734-743, 2014 | 1501 | 2014 |
| Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study RA Burger, MW Sill, BJ Monk, BE Greer, JI Sorosky Journal of clinical oncology 25 (33), 5165-5171, 2007 | 1050 | 2007 |
| Carcinogenic human papillomavirus infection M Schiffman, J Doorbar, N Wentzensen, S De Sanjosé, C Fakhry, ... Nature reviews Disease primers 2 (1), 1-20, 2016 | 906 | 2016 |
| Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer JB Welsh, PP Zarrinkar, LM Sapinoso, SG Kern, CA Behling, BJ Monk, ... Proceedings of the National Academy of Sciences 98 (3), 1176-1181, 2001 | 879 | 2001 |
| Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study BJ Monk, MW Sill, DS McMeekin, DE Cohn, LM Ramondetta, ... Journal of clinical oncology 27 (28), 4649, 2009 | 766 | 2009 |
| Latest research and treatment of advanced-stage epithelial ovarian cancer RL Coleman, BJ Monk, AK Sood, TJ Herzog Nature reviews Clinical oncology 10 (4), 211-224, 2013 | 586 | 2013 |
| Pembrolizumab for persistent, recurrent, or metastatic cervical cancer N Colombo, C Dubot, D Lorusso, MV Caceres, K Hasegawa, ... New England Journal of Medicine 385 (20), 1856-1867, 2021 | 538 | 2021 |
| Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) KS Tewari, MW Sill, RT Penson, H Huang, LM Ramondetta, LM Landrum, ... The Lancet 390 (10103), 1654-1663, 2017 | 536 | 2017 |
| Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based … M Markman, PY Liu, S Wilczynski, B Monk, LJ Copeland, RD Alvarez, ... Journal of Clinical Oncology 21 (13), 2460-2465, 2003 | 525 | 2003 |
| Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer BJ Monk, TJ Herzog, SB Kaye, CN Krasner, JB Vermorken, FM Muggia, ... Journal of clinical oncology 28 (19), 3107-3114, 2010 | 498 | 2010 |
| Adhesions after extensive gynecologic surgery: clinical significance, etiology, and prevention BJ Monk, ML Berman, FJ Montz American journal of obstetrics and gynecology 170 (5), 1396-1403, 1994 | 457 | 1994 |
| Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial KN Moore, AA Secord, MA Geller, DS Miller, N Cloven, GF Fleming, ... The Lancet Oncology 20 (5), 636-648, 2019 | 448 | 2019 |
| Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study BJ Monk, MW Sill, RA Burger, HJ Gray, TE Buekers, LD Roman Journal of clinical oncology 27 (7), 1069, 2009 | 420 | 2009 |
| Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer KS Tewari, RA Burger, D Enserro, BM Norquist, EM Swisher, MF Brady, ... Journal of Clinical Oncology 37 (26), 2317, 2019 | 385 | 2019 |
| Incorporation of pazopanib in maintenance therapy of ovarian cancer A Du Bois, A Floquet, JW Kim, J Rau, JM Del Campo, M Friedlander, ... Journal of clinical oncology 32 (30), 3374-3382, 2014 | 379 | 2014 |
| Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer JK Chan, MF Brady, RT Penson, H Huang, MJ Birrer, JL Walker, ... New England Journal of Medicine 374 (8), 738-748, 2016 | 377 | 2016 |
